



ASX ANNOUNCEMENT

19 May 2014

Vesting of Unlisted Options

Cynata Therapeutics Ltd (ASX: CYP), advises that the vesting conditions on 125,000 Tranche C and 125,000 Tranche D unlisted options issued to Mr Howard Digby were met on 17 May 2014. The unlisted options are exercisable at \$0.40 each on or before 9 September 2016.

Details of the vesting conditions are set out on page 80 of the Prospectus lodged with the ASX on 14 October 2013.

The unlisted options remain subject to escrow until 29 November 2015.

Media contacts: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.